Table 3.
Reported LODs and LOQs (in μg/kg fresh weight) for TTX and its analogues
| TTX/TTX analogue | Country | |||||
|---|---|---|---|---|---|---|
| United Kingdoma | Netherlands | Greece | ||||
| LOQ | LOD | LOQ | LOD | LOQ | LOD | |
| TTX | 1 | 0.5 | 10–25 | 3–5 | 7.2 | 2.2 |
| 11‐norTTX‐6‐ol | 6.4 | 2.13 | – | – | n.r. | n.r. |
| 11‐oxoTTX | 6.4 | 2.13 | – | – | – | – |
| 4,9‐anhydroTTX | 1.2 | 0.4 | n.r. | n.r. | 21.1 | 6.2 |
| 4‐epiTTX | 0.12 | 0.04 | 10–25 | 3–5 | 7.6 | 2.3 |
| 5,6,11‐trideoxyTTX | 1.03 | 0.34 | – | – | n.r. | n.r. |
| mono‐deoxyTTX | 6.4 | 2.13 | – | – | – | – |
| 5‐deoxyTTX | – | – | – | – | n.r. | n.r. |
| 11‐deoxyTTX | – | – | – | – | n.r. | n.r. |
LOD: limit of detection; LOQ: limit of quantification; n.r.: not reported; – : not analysed; TTX: tetrodotoxin.
a
In the case of analogues in samples from the UK, with the agreement of the Data Provider, LOQ = minimum of reported values, LOD = LOQ/3. For 11‐oxoTTX and mono‐deoxyTTX, the highest LOQ/LOD identified among the other analogues has been used as an assumption.